Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894796138> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W2894796138 abstract "3587 Background: There are few therapies for second-line KRASm CRC. Inhibiting downstream signal transduction may offer therapeutic options. Use of selumetinib (MEK 1/2 inhibitor; AstraZeneca) is supported by preclinical and clinical evidence. We designed a dose-finding/phase II study of IRI + SEL in KRASm CRC. Methods: Eligibility included: KRASm or BRAFm CRC with measurable disease progressing after 1st-line therapy with an oxalipatin + bevacizumab regimen; PS 0-1; acceptable organ function. Patients (Pts) were treated with IRI 180 mg/m2 iv q2w and SEL 50 or 75 mg po bid. Dose escalation was traditional 3+3 (50 mg bid SEL, then 75 mg bid). In Part B/phase II, primary endpoint was PI-determined response rate (RR) by RECIST. A Simon 2-stage design allowed expansion to 45 pts if ≥1 responses in 20 pts was seen; ≥4/45 responses would be encouraging, when compared to historical RR of 4% (and median PFS 2.5 mo) [EPIC, Sobrero 2008], with approximately 90% power to detect an ORR of 15% at the 10% alpha level (one-sided). Results: N =32 pts entered; 31 treated. Median age was 54 (27-75) yrs; 18 male and 24 Caucasian. The first 3 pts tolerated SEL 50 mg bid without DLT and the remaining 28 were treated at 75 bid. Median number of cycles on study was 3.5 and median PFS was 3.4 mo. Grade 3 AEs included (N): diarrhea 3, fatigue 2, neutropenia 2, and 1 each thrombocytopenia, enteritis, GI bleed, rash. There was one Grade 4 neutropenia. The best PI-reported response included 3 (10%) confirmed PR and 16 (52%) SD [including 1 unconfirmed PR]. 6 patients were on study for more than 6 (up to 22) months. The study was terminated early due to non-protocol considerations. Conclusions: In this small study, the RR of 10% and med PFS of 3.4 mo in pts with KRASm CRC treated with IRI + SEL in 2 nd line are promising compared with prior studies in non-selected patients. MEK inhibition in KRASm CRC should be explored further. Supported in part by AstraZeneca." @default.
- W2894796138 created "2018-10-12" @default.
- W2894796138 creator A5003463083 @default.
- W2894796138 creator A5005375804 @default.
- W2894796138 creator A5007560050 @default.
- W2894796138 creator A5010925062 @default.
- W2894796138 creator A5014497423 @default.
- W2894796138 creator A5015750678 @default.
- W2894796138 creator A5017215021 @default.
- W2894796138 creator A5034428260 @default.
- W2894796138 creator A5045441776 @default.
- W2894796138 creator A5048973199 @default.
- W2894796138 creator A5067387322 @default.
- W2894796138 creator A5078259926 @default.
- W2894796138 creator A5085023946 @default.
- W2894796138 date "2013-05-20" @default.
- W2894796138 modified "2023-10-17" @default.
- W2894796138 title "The MEK inhibitor selumetinib ([SEL], AZD6244, ARRY-142886) plus irinotecan (IRI) as second-line therapy for KRAS-mutated (KRASm) metastatic colorectal cancer (CRC)." @default.
- W2894796138 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.3587" @default.
- W2894796138 hasPublicationYear "2013" @default.
- W2894796138 type Work @default.
- W2894796138 sameAs 2894796138 @default.
- W2894796138 citedByCount "1" @default.
- W2894796138 countsByYear W28947961382014 @default.
- W2894796138 crossrefType "journal-article" @default.
- W2894796138 hasAuthorship W2894796138A5003463083 @default.
- W2894796138 hasAuthorship W2894796138A5005375804 @default.
- W2894796138 hasAuthorship W2894796138A5007560050 @default.
- W2894796138 hasAuthorship W2894796138A5010925062 @default.
- W2894796138 hasAuthorship W2894796138A5014497423 @default.
- W2894796138 hasAuthorship W2894796138A5015750678 @default.
- W2894796138 hasAuthorship W2894796138A5017215021 @default.
- W2894796138 hasAuthorship W2894796138A5034428260 @default.
- W2894796138 hasAuthorship W2894796138A5045441776 @default.
- W2894796138 hasAuthorship W2894796138A5048973199 @default.
- W2894796138 hasAuthorship W2894796138A5067387322 @default.
- W2894796138 hasAuthorship W2894796138A5078259926 @default.
- W2894796138 hasAuthorship W2894796138A5085023946 @default.
- W2894796138 hasConcept C121608353 @default.
- W2894796138 hasConcept C126322002 @default.
- W2894796138 hasConcept C143998085 @default.
- W2894796138 hasConcept C184235292 @default.
- W2894796138 hasConcept C203092338 @default.
- W2894796138 hasConcept C2776087337 @default.
- W2894796138 hasConcept C2776694085 @default.
- W2894796138 hasConcept C2777802072 @default.
- W2894796138 hasConcept C2778332735 @default.
- W2894796138 hasConcept C2780259306 @default.
- W2894796138 hasConcept C2781187634 @default.
- W2894796138 hasConcept C2781249067 @default.
- W2894796138 hasConcept C2781413609 @default.
- W2894796138 hasConcept C526805850 @default.
- W2894796138 hasConcept C535046627 @default.
- W2894796138 hasConcept C57074206 @default.
- W2894796138 hasConcept C71924100 @default.
- W2894796138 hasConcept C86803240 @default.
- W2894796138 hasConcept C95444343 @default.
- W2894796138 hasConcept C98274493 @default.
- W2894796138 hasConceptScore W2894796138C121608353 @default.
- W2894796138 hasConceptScore W2894796138C126322002 @default.
- W2894796138 hasConceptScore W2894796138C143998085 @default.
- W2894796138 hasConceptScore W2894796138C184235292 @default.
- W2894796138 hasConceptScore W2894796138C203092338 @default.
- W2894796138 hasConceptScore W2894796138C2776087337 @default.
- W2894796138 hasConceptScore W2894796138C2776694085 @default.
- W2894796138 hasConceptScore W2894796138C2777802072 @default.
- W2894796138 hasConceptScore W2894796138C2778332735 @default.
- W2894796138 hasConceptScore W2894796138C2780259306 @default.
- W2894796138 hasConceptScore W2894796138C2781187634 @default.
- W2894796138 hasConceptScore W2894796138C2781249067 @default.
- W2894796138 hasConceptScore W2894796138C2781413609 @default.
- W2894796138 hasConceptScore W2894796138C526805850 @default.
- W2894796138 hasConceptScore W2894796138C535046627 @default.
- W2894796138 hasConceptScore W2894796138C57074206 @default.
- W2894796138 hasConceptScore W2894796138C71924100 @default.
- W2894796138 hasConceptScore W2894796138C86803240 @default.
- W2894796138 hasConceptScore W2894796138C95444343 @default.
- W2894796138 hasConceptScore W2894796138C98274493 @default.
- W2894796138 hasLocation W28947961381 @default.
- W2894796138 hasOpenAccess W2894796138 @default.
- W2894796138 hasPrimaryLocation W28947961381 @default.
- W2894796138 isParatext "false" @default.
- W2894796138 isRetracted "false" @default.
- W2894796138 magId "2894796138" @default.
- W2894796138 workType "article" @default.